Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication

Richard Rosenquist, MD
Section Editors
Lisa Warren, MD
Lawrence LK Leung, MD
Deputy Editor
Marianna Crowley, MD


Neuraxial anesthesia techniques are used in many settings, as intraoperative anesthetics, for postoperative pain control, in the peripartum period, and in the management of chronic pain. Patients who are candidates for neuraxial anesthesia techniques may be on chronic antiplatelet or anticoagulation therapy, may require anticoagulation during or following surgery, or may receive prophylactic medication for venous thromboembolism in the perioperative period. These patients are at increased risk for hemorrhagic complications of neuraxial techniques.

For the purpose of this topic, neuraxial anesthesia refers to spinal or epidural anesthesia procedures that may be performed for surgical anesthesia or perioperative analgesia. This topic will discuss the level of risk, the management of antithrombotic (anticoagulant and antiplatelet) medication in conjunction with neuraxial anesthesia, and the timing of neuraxial anesthesia relative to antithrombotic medication in non-pregnant patients. Neuraxial procedures in obstetrical patients and patients being treated for chronic pain are discussed in more detail elsewhere. (See "Adverse effects of neuraxial analgesia and anesthesia for obstetrics".). In-depth discussion of neuraxial anesthesia and analgesia is also found elsewhere. (See "Neuraxial analgesia for labor and delivery (including instrumented delivery)" and "Spinal anesthesia: Technique" and "Overview of neuraxial anesthesia" and "Epidural and combined spinal-epidural anesthesia: Techniques".)

Other types of nerve blocks are discussed separately. While in general the recommendations presented here are applicable to patients having paravertebral and other "deep" blocks (in anatomic locations not amenable to the application of pressure to control hemorrhage), recommendations regarding antithrombotic medication may not be as rigid for more superficial blocks; this is discussed elsewhere. (See "Overview of peripheral nerve blocks" and "Lower extremity nerve blocks: Techniques".)


Bleeding is the major complication of antithrombotic therapy. When this bleeding occurs in the closed space of the spinal canal, the expanding hematoma causes increased pressure on the spinal cord or cauda equina, which in turn may lead to spinal cord ischemia and infarction.

Following neuraxial anesthesia (spinal or epidural), bleeding is most commonly from vessels in the prominent venous plexus of the epidural space, although it can be in the subdural or subarachnoid spaces. We will refer to this bleeding as spinal epidural hematoma (SEH); the considerations discussed below do not differ for other bleeding locations within the spinal canal.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 21, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35:64.
  2. Breivik H, Bang U, Jalonen J, et al. Nordic guidelines for neuraxial blocks in disturbed haemostasis from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand 2010; 54:16.
  3. Vandermeulen E. Anaesthesia and new antithrombotic drugs. Curr Opin Anaesthesiol 2005; 18:353.
  4. Kozek-Langenecker SA, Fries D, Gütl M, et al. [Locoregional anesthesia and coagulation inhibitors. Recommendations of the Task Force on Perioperative Coagulation of the Austrian Society for Anesthesiology and Intensive Care Medicine]. Anaesthesist 2005; 54:476.
  5. Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, et al. [Hemostasis-altering drugs and techniques for regional anesthesia and analgesia: safety recommendations]. Rev Esp Anestesiol Reanim 2005; 52:248.
  6. Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27:999.
  7. An JX, Fang QW, Sullivan EA, Williams JP. Spine surgery may cause more spinal epidural hematomas than spinal puncture. Chin Med J (Engl) 2013; 126:286.
  8. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. Anesthesiology 2004; 101:950.
  9. Bateman BT, Mhyre JM, Ehrenfeld J, et al. The risk and outcomes of epidural hematomas after perioperative and obstetric epidural catheterization: a report from the Multicenter Perioperative Outcomes Group Research Consortium. Anesth Analg 2013; 116:1380.
  10. Tryba M. [Epidural regional anesthesia and low molecular heparin: Pro]. Anasthesiol Intensivmed Notfallmed Schmerzther 1993; 28:179.
  11. D'Angelo R, Smiley RM, Riley ET, Segal S. Serious complications related to obstetric anesthesia: the serious complication repository project of the Society for Obstetric Anesthesia and Perinatology. Anesthesiology 2014; 120:1505.
  12. Leffert LR, Dubois HM, Butwick AJ, et al. Neuraxial Anesthesia in Obstetric Patients Receiving Thromboprophylaxis With Unfractionated or Low-Molecular-Weight Heparin: A Systematic Review of Spinal Epidural Hematoma. Anesth Analg 2017; 125:223.
  13. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79:1165.
  14. Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23:164.
  15. Lee LA, Posner KL, Domino KB, et al. Injuries associated with regional anesthesia in the 1980s and 1990s: a closed claims analysis. Anesthesiology 2004; 101:143.
  16. https://www.asra.com/advisory-guidelines/article/1/anticoagulation-3rd-edition.
  17. Ruff RL, Dougherty JH Jr. Complications of lumbar puncture followed by anticoagulation. Stroke 1981; 12:879.
  18. Liu SS, Mulroy MF. Neuraxial anesthesia and analgesia in the presence of standard heparin. Reg Anesth Pain Med 1998; 23:157.
  19. Ho AM, Li PT, Karmakar MK. Risk of hematoma after epidural anesthesia and analgesia for cardiac surgery. Anesth Analg 2006; 103:1327; author reply 1327.
  20. Chaney MA. Intrathecal and epidural anesthesia and analgesia for cardiac surgery. Anesth Analg 2006; 102:45.
  21. Royse CF. High thoracic epidural anaesthesia for cardiac surgery. Curr Opin Anaesthesiol 2009; 22:84.
  22. Gallus AS, Hirsh J, Tutle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973; 288:545.
  23. Leonardi MJ, McGory ML, Ko CY. The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials. Arch Surg 2006; 141:790.
  24. King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest 2007; 131:507.
  25. Schroeder DR. Statistics: detecting a rare adverse drug reaction using spontaneous reports. Reg Anesth Pain Med 1998; 23:183.
  26. Lojewski B, Bacher P, Iqbal O, et al. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Semin Thromb Hemost 1995; 21:228.
  27. US FDA Alert: Low Molecular Weight Heparins: Drug Safety Communication - Recommendations to Decrease Risk of Spinal Column Bleeding and Paralysis. US FDA website. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm373918.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery (Accessed on November 14, 2013).
  28. Benzon HT, Avram MJ, Green D, Bonow RO. New oral anticoagulants and regional anaesthesia. Br J Anaesth 2013; 111 Suppl 1:i96.
  29. Wysokinski WE, McBane RD 2nd. Periprocedural bridging management of anticoagulation. Circulation 2012; 126:486.
  30. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022406s019s020lbl.pdf.
  31. Urmey WF, Rowlingson J. Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Reg Anesth Pain Med 1998; 23:146.
  32. Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984; 33:155.
  33. Benzon HT, McCarthy RJ, Benzon HA, et al. Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. Br J Anaesth 2011; 107:966.
  34. Morales Ciancio RA, Drain O, Rillardon L, Guigui P. Acute spontaneous spinal epidural hematoma: an important differential diagnosis in patients under clopidogrel therapy. Spine J 2008; 8:544.
  35. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:257S.
Topic Outline